WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide. [Read more…]
Kimera Labs Introduces the Ross Unit, a Standard Measurement for Exosome Potency and Characterization
Although long overlooked, exosomes have been gaining momentum due to their potential for use as cell-free therapeutics. Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. [Read more…]
What Is Carpal Tunnel? Learn the Symptoms, Causes, and Cures
With those first few wrist twinges, you may start to research what is carpal tunnel and what it isn’t. As the condition progresses, carpal tunnel syndrome symptoms become unmistakable. Many people worry that surgery is their only hope to ease this chronic problem. However, other carpal tunnel syndrome therapy options exist.
In this article:
Alternate Ocean Offers to Acquire Largest Cord Blood Bank in China (GCBC) for $5/Share
HONG KONG, March 2, 2021 — On March 2, 2021, Global Cord Blood Corporation (GCBC) announced that it received a non-binding proposal letter from Alternate Ocean Investment Company Limited (“Alternate Ocean”), a wholly-owned subsidiary of Haitong International Securities Group Limited.
The proposal letter offers for Alternate Ocean, acting on behalf of certain funds and entities that it manages or advises, to acquire all of the outstanding ordinary shares of GCBC for US$5.00 per ordinary share in cash. [Read more…]
Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source’s Scientific Advisory Board
Director of Pediatric Hematology-Oncology and Barron Hilton Professor & Chair in Pediatrics at City of Hope National Medical Center Brings Decades of Innovation to Cell Source’s Scientific Leadership Team
February 25, 2021 – New York, NY – Cell Source, Inc. (OTC: CLCS) (“Cell Source” or the “Company”), a developer of Veto Cell-based innovative immunotherapy technologies that facilitate mismatched donor stem cell (e.g. bone marrow) and organ transplants and other cell therapy treatments with an improved safety profile achieved through the active management of immune response, today announced that Joseph Rosenthal, M.D., M.H.C.M. JD, has joined its Scientific Advisory Board. Dr. Rosenthal is currently the Director of Pediatric Hematology-Oncology and Barron Hilton Professor & Chair in Pediatrics at City of Hope National Medical Center in Duarte, CA. [Read more…]
- « Previous Page
- 1
- …
- 170
- 171
- 172
- 173
- 174
- …
- 336
- Next Page »